SGLT-2受体抑制剂治疗糖尿病患者的效果及对ET、HOMA-β、FMD、NO水平的影响  

Effect of SGLT-2 Receptor Inhibitor on Diabetes Patients and Its Effects on ET,HOMA-β,FMD and NO Levels

作　　者：邓晓君 DENG Xiaojun(Jiamusi Central Hospital,Jiamusi 154002,China)

机构地区：[1]黑龙江省佳木斯市中心医院,黑龙江佳木斯154002

出　　处：《中国医学创新》2021年第19期66-70,共5页Medical Innovation of China

摘　　要：目的:探讨SGLT-2受体抑制剂治疗糖尿病患者的效果及对胰岛β细胞功能指数(HOMA-β)、内皮舒张功能(FMD)、内皮素(ET)及一氧化氮(NO)水平的影响。方法:选取2019年6月-2020年1月本院收治的糖尿病患者78例,依据治疗方案的不同将其分为对照组与研究组,每组39例。对照组采用利拉鲁肽治疗,研究组采用SGLT-2受体抑制剂治疗。对比两组干预前后HOMA-β、FMD、ET、NO、血糖指标及临床疗效。结果:干预后,两组HOMA-β与FMD均高于干预前,且研究组均高于对照组(P<0.05)。干预后,两组NO水平均高于干预前,且ET水平均低于干预前(P<0.05);干预后,研究组ET水平低于对照组,且NO水平高于对照组(P<0.05)。干预后,两组FBG、2 h PBG及HbA1c水平均低于干预前,且研究组均低于对照组(P<0.05)。研究组治疗总有效率高于对照组(P<0.05)。结论:SGLT-2受体抑制剂治疗糖尿病患者可有效提升临床效果,改善ET、HOMA-β、FMD、NO水平,有效调节血糖水平,效果理想,可考虑推广。Objective:To investigate the effect of SGLT-2 receptor inhibitor in the treatment of diabetes patients and the effects on the levels of isletβ-cell function index(HOMA-β),flow-mediated dilation(FMD),endothelin(ET)and nitric oxide(NO).Method:A total of 78 patients with diabetes treated in our hospital from June 2019 to January 2020 were selected.They were divided into control group and study group according to different treatment regimens,with 39 cases in each group.The control group was treated with Liraglutide and the study group was treated with SGLT-2 receptor inhibitor.HOMA-β,FMD,ET,NO,blood glucose indexes before and after intervention and clinical efficacy were compared between the two groups.Result:After intervention,HOMA-β and FMD in both groups were higher than before intervention,and those in the study group were higher than those in the control group(P<0.05).After intervention,NO levels of both groups were higher than before intervention,and ET levels of both groups were lower than before intervention(P<0.05).After intervention,the ET level in the study group was lower than that in the control group,and the NO level was higher than that in the control group(P<0.05).After intervention,FBG,2 h PBG and HbA1c levels in both groups were lower than before intervention,and those in the study group were lower than those in the control group(P<0.05).The total effective rate of study group was higher than that of control group(P<0.05).Conclusion:SGLT-2 receptor inhibitor in the treatment of diabetes patients can effectively enhance the clinical efficacy,improve the levels of ET,HOMA-β,FMD,NO,and effectively regulate the blood glucose level,the effect is ideal,which can be considered to promote.

关 键 词：糖尿病 SGLT-2受体抑制剂 内皮素 胰岛β细胞功能指数 内皮舒张功能 一氧化氮 

分 类 号：R587.1[医药卫生—内分泌]